← All trials
NCT01839175
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2013
- Primary completion
- Jul 1, 2014
- Completion date
- Feb 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisCollaborator
Drugs studied
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- rotavirus vaccine, live, oral, pentavalent
- rotavirus vaccine, live, oral, pentavalent
- measles, mumps, and rubella vaccine
- measles, mumps, and rubella vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- hexavalent pneumococcal polysaccharide vaccine
- hexavalent pneumococcal polysaccharide vaccine
- Monovalent group C meningococcal vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.